First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1

BACKGROUND: In CheckMate 227 Part 1 (NCT02477826), first-line nivolumab plus ipilimumab demonstrated long-term durable overall survival (OS) benefit versus chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC), regardless of tumor programmed death ligand 1 (PD-L1) expression. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishio, Makoto, Ohe, Yuichiro, Ikeda, Satoshi, Yokoyama, Toshihide, Hayashi, Hidetoshi, Fukuhara, Tatsuro, Sato, Yuki, Tanaka, Hiroshi, Hotta, Katsuyuki, Sugawara, Shunichi, Daga, Haruko, Okamoto, Isamu, Kasahara, Kazuo, Naito, Tateaki, Li, Li, Gupta, Ravi G., Bushong, Judith, Mizutani, Hideaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542710/
https://www.ncbi.nlm.nih.gov/pubmed/37548831
http://dx.doi.org/10.1007/s10147-023-02390-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542710/
https://www.ncbi.nlm.nih.gov/pubmed/37548831
http://dx.doi.org/10.1007/s10147-023-02390-2

Ejemplares similares